Integration of DNA barcoding and nanotechnology in drug delivery.

In recent years' development in nanotechnology utilization of DNA barcodes with potential benefit of nanoparticulate system is a hallmark for novel advancement in healthcare, biomedical and research sector. Interplay of biological barcoding with nanodimensional system encompasses innovative technologies to offer unique advantages of ultra-sensitivity, error-free, accuracy with minimal label reagents, and less time consumption in comparison to conventional techniques like ELISA, PCR, culture media, electrophoresis. DNA barcoding systems used as universal novel tool for identification and multiplex structural detection of proteins, DNAs, toxins, allergens, and nucleic acids of humans, viruses, animals, bacteria, plants as well as personalized treatment in ovarian cancer, AIDS-related Kaposi sarcoma, breast cancer and cardiovascular diseases.

Performance study of a sterilization box using a combination of heat and ultraviolet light irradiation for the prevention of COVID-19.

SARS-CoV-2 virus and other pathogenic microbes are transmitted to the environment through contacting surfaces, which need to be sterilized for the prevention of COVID-19 and related diseases. In this study, a prototype of a cost-effective sterilization box is developed to disinfect small items. The box utilizes ultra violet (UV) radiation with heat.

Salivary IgA, Interleukin-1β and MMP-8 as Salivary Biomarkers in Chronic Periodontitis Patients.

Objective: To compare the clinical parameters and levels of salivary immunoglobulin A (IgA), Interleukin-1β (IL-1β) and matrix metalloproteinase-8 (MMP-8) in patients with moderate to severe chronic periodontitis and in individuals with healthy gingiva.

Methods: Levels of clinical parameters plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAL) and bleeding on probing (BOP) along with salivary biomarkers salivary IgA, IL-1β and MMP-8 were recorded among 50 adults (30 test subjects with moderate to severe generalised chronic periodontitis, constituting group A, and 20 periodontally healthy controls - group B). Clinical evaluation was done before oral prophylaxis, and 6 weeks and 12 weeks after oral prophylaxis, and saliva samples were obtained before and 12 weeks after oral prophylaxis.